🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Fergus Keane

University College Dublin

ORCID: 0000-0001-6651-2090

Also affiliated with Memorial Sloan Kettering Cancer Center, St. Vincent's University Hospital

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

1in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Top data-sharing exemplar

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Data from Clinico-genomic Characterization of ATM and HRD in Pancreas Cancer: Application for Practice

(2023)10.1158/1078-0432.c.6532713.v1
Top 100%
0DataRank
Top 100%0 citations

Catherine O’Connor, Chaitanya Bandlamudi, Daniella Forman, Joanne F. Chou, Shigeaki Umeda +11 more

Papers

Driven by 13 papers — median percentile 0. Top paper: “Neoplasia risk in patients with Lynch syndrome treated with immune checkpoint blockade”.

Neoplasia risk in patients with Lynch syndrome treated with immune checkpoint blockade

Nature Medicine(2023)10.1038/s41591-023-02544-9
N/A
0.550DataRank · unranked
38 citations

Michael B. Foote, Benoı̂t Rousseau, Henry Walch, Yelena Kemel, Allison L. Richards +33 more

Clinico-genomic Characterization of ATM and HRD in Pancreas Cancer: Application for Practice

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-1483
N/A
0.546DataRank · unranked
37 citations

Catherine O’Connor, Chaitanya Bandlamudi, Daniella Forman, Joanne F. Chou, Shigeaki Umeda +11 more

Phase 2 trial of pembrolizumab and olaparib (POLAR) maintenance for patients (pts) with metastatic pancreatic cancer (mPDAC): Two cohorts B non-core homologous recombination deficiency (HRD) and C exceptional response to platinum-therapy.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.4140
N/A
0.449DataRank · unranked
19 citations

Catherine O’Connor, Joanne F. Chou, Carly Schwartz, Anna M. Varghese, Mary Pat Larsen +15 more

Precision medicine for pancreatic cancer: characterizing the clinicogenomic landscape and outcomes of KRAS G12C-mutated disease

JNCI Journal of the National Cancer Institute(2024)10.1093/jnci/djae095
N/A
0.373DataRank · unranked
11 citations

Joanne F. Chou, Henry Walch, Joshua D. Schoenfeld, Anupriya Singhal, Darren Cowzer +12 more

Dramatic, durable response to therapy in gBRCA2-mutated pancreas neuroendocrine carcinoma: opportunity and challenge

npj Precision Oncology(2023)10.1038/s41698-023-00376-x
N/A
0.366DataRank · unranked
6 citations

Raazi Bajwa, Pier Selenica, Wungki Park, Michael H. A. Roehrl, Jorge S. Reis‐Filho +3 more

Molecular and Clinical Determinants of Acquired Resistance and Treatment Duration for Targeted Therapies in Colorectal Cancer

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-23-4005
N/A
0.345DataRank · unranked
9 citations

Fergus Keane, Henry Walch, Joanne F. Chou, Jenna Sinopoli, Silvia Palladino +13 more

Acquired High Tumor Mutational Burden and Activity of Immunotherapy after Targeted Therapy in Microsatellite Stable Colorectal Cancer

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-25-2566
N/A
0.292DataRank · unranked
6 citations

Oliver Artz, Haochen Zhang, Elias-Ramzey Karnoub, Peter Ntiamoah, Caroline Weipert +15 more

Clinicogenomic predictors of outcomes in patients with hepatocellular carcinoma treated with immunotherapy

The Oncologist(2024)10.1093/oncolo/oyae110
N/A
0.269DataRank · unranked
5 citations

Joanne F. Chou, Henry Walch, Fergus Keane, Danny N. Khalil, Jinru Shia +20 more

Clinical utility and tissue concordance of circulating tumor DNA in pancreatic ductal adenocarcinoma

JNCI Journal of the National Cancer Institute(2025)10.1093/jnci/djaf139
N/A
0.241DataRank · unranked
4 citations

Lily V. Saadat, Catherine O’Connor, Joanne F. Chou, Anita S. Bowman, Fei Xu +18 more

Pembrolizumab and Olaparib (POLAR) Maintenance Therapy in Metastatic Pancreatic Cancer With or Without Homologous Repair Deficiency: A Biomarker Selected Phase II Trial

Research Square(2025)10.21203/rs.3.rs-7334701/v1
N/A
0.214DataRank · unranked
3 citations

Catherine O’Connor, Joanne F. Chou, Marc Hilmi, Zeynep Tarcan, Carly Schwartz +61 more

Immunogenomic characterization of biliary tract cancers: Biomarker enrichment for benefit to immune checkpoint blockade.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.4083
N/A
0.208DataRank · unranked
3 citations

Fergus Keane, Chaitanya Bandlamudi, Mark T.A. Donoghue, Paulino Tallón de Lara, James J. Harding +15 more

Adjuvant modified FOLFIRINOX for resected pancreatic adenocarcinoma: clinical insights and genomic features from a large contemporary cohort

JNCI Journal of the National Cancer Institute(2024)10.1093/jnci/djae269
N/A
0DataRank · unranked
3 citations

Catherine O’Connor, Drew Moss, Joanne F. Chou, Maria Perry, Fionnuala Crowley +26 more

Data from Clinico-genomic Characterization of ATM and HRD in Pancreas Cancer: Application for Practice

(2023)10.1158/1078-0432.c.6532713.v1
Top 100%
0DataRank
Top 100%0 citations

Catherine O’Connor, Chaitanya Bandlamudi, Daniella Forman, Joanne F. Chou, Shigeaki Umeda +11 more